Beihai Gofar Chuanshan Biological Co (600538) Fair Value & Analysis
Basic Materials · CN · Market cap 3.0B CNY
Fair value as of: Jun 24, 2026
Analysis
Beihai Gofar Chuanshan Biological Co (600538) currently trades at ¥5.93, while our model-based Fair Value estimate is ¥3.94 — implying the stock looks roughly 33.6% overvalued today. We read business quality at 93/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, pharmacies, health centers, clinics, directly operated stores, general agents, distributors, and allocations. It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; brand gastrointestinal granules, honeysuckle oral solution, and children's syrup under the Guofa brand; and traumatic injury medicated wine, and sea snake medicated wine under the Haima brand. In addition, the company produces and sells forensic DNA testing equipment, reagents, and consumables; and provides technical services, including DNA testing services. Further, it engages in culture and a…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Beihai Gofar Chuanshan Biological Co (600538) undervalued?
What is the fair value of 600538?
What is the quality score of 600538?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.